In Phase 2, we are combatting chronic shortages of critical nuclear isotopes in medicine, domestically and across the globe. These shortages directly impact patient diagnoses and treatment of heart disease, cancer, and other serious illnesses. We plan to use the neutrons produced by fusion as a driver to produce both therapeutic and diagnostic medical isotopes.
In targeted cancer therapy, our cancer-fighting medical isotope, lutetium-177, is paired with cancer-seeking medicine. They form a smart compound that directly targets and attacks specific cells, leaving surrounding tissue relatively untouched. We are rapidly scaling our production of Lu-177 to meet the demand created by exciting new therapies. Our goal is to become the first vertically integrated manufacturer of Lu-177 in the world.
Early detection of heart disease, cancer and many other diseases is critical when it comes to providing patients with enhanced treatment options, planning flexibility, lower-cost interventions and more.
Molybdenum-99 isotope is the hardest-working diagnostic medical isotope in the world, powering approximately 40 million patient scans each year, with roughly 50% of those in North America. We have plans to satisfy more than half the world’s demand through the company’s mass production facility, The Chrysalis, which is currently under construction in Janesville, Wisconsin.
We've designed our four-phased approach to produce meaningful outcomes at each stage as we work toward fusion energy.
We're proud to have accomplished key milestones during Phase 2: Producing Medical Isotopes.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.
